



Murdoch
UNIVERSITY

MURDOCH RESEARCH REPOSITORY

*This is the author's final version of the work, as accepted for publication following peer review but without the publisher's layout or pagination.
The definitive version is available at*

<http://dx.doi.org/10.1016/j.seizure.2015.01.014>

Silbert, B.I., Heaton, A.E., Cash, R.F.H., James, I., Dunne, J.W., Lawn, N.D., Silbert, P.L., Mastaglia, F.L. and Thickbroom, G.W. (2015) Evidence for an excitatory GABAA response in human motor cortex in idiopathic generalised epilepsy. *Seizure*, 26 . pp. 36-42.

<http://researchrepository.murdoch.edu.au/26063/>

Copyright: © 2015 British Epilepsy Association
It is posted here for your personal use. No further distribution is permitted.

1 **Evidence for an excitatory GABA_A response in human motor cortex in**
2 **idiopathic generalised epilepsy**

3 *Benjamin I Silbert^a, Alexandra E Heaton^a, Robin FH Cash^{a,b}, Ian James^c, John W Dunne^d,*
4 *Nicholas D Lawn^d, Peter L Silbert^d, Frank L Mastaglia^a, Gary W Thickbroom^a*

5 ^aWestern Australian Neuroscience Research Institute, University of Western Australia, Perth,
6 Western Australia, Australia. [Western Australian Neuroscience Research Institute, 4th Floor,
7 A Block, QEII Medical Centre, Verdun Street, Nedlands, Western Australia 6009, Australia]

8 ^bDivision of Brain, Imaging and Behaviour - Systems Neuroscience, Toronto Western
9 Research Institute, University Health Network, Toronto, Ontario, Canada. [Division of Brain,
10 Imaging and Behaviour - Systems Neuroscience, Toronto Western Research Institute, 339
11 Bathurst Street, MP14-324, Toronto, Ontario M5T 2S8, Canada]

12 ^cCentre for Clinical Immunology and Biomedical Statistics, Institute for Immunology and
13 Infectious Diseases, Murdoch University, Perth, Western Australia, Australia. [Centre for
14 Clinical Immunology and Biomedical Statistics, Institute for Immunology and Infectious
15 Diseases, Building 390, Murdoch University, Discovery Way, Murdoch, Western Australia
16 6150, Australia]

17 ^dDepartment of Neurology, Royal Perth Hospital, Perth, Western Australia, Australia.
18 [Department of Neurology, Level 8, A Block, Royal Perth Hospital, GPO Box X2213, Perth,
19 Western Australia 6001, Australia]

20 **Address for Correspondence:**

21 GW Thickbroom
22 M518, University of Western Australia
23 Nedlands, Western Australia 6009
24 Australia

25 Email: gary.thickbroom@gmail.com Phone: +61 8 9346 4479

26 **Conflict of interest:** None of the authors have potential conflicts of interest to be disclosed.

27 **Highlights:**

- 28 1. TMS was used to explore GABA-mediated inhibition in IGE
- 29 2. Post-synaptic GABA_B inhibition (LICI) was normal, but pre-synaptic LICF reduced
- 30 3. GABA_A inhibition (SICI) was reduced in untreated but not treated IGE
- 31 4. When tested during GABA_B inhibition, the SICI protocol was excitatory
- 32 5. During ongoing GABA_B inhibition, GABA_A activation may be excitatory

33

33 **Abstract**

34 **Purpose:** Impaired GABAergic inhibition has been implicated in the pathophysiology of
35 epilepsy. The possibility of a paradoxical excitatory effect of GABA in epilepsy has been
36 suggested, but has not been investigated *in vivo*. We investigated pre- and post-synaptic
37 GABAergic mechanisms in patients with idiopathic generalised epilepsy (IGE).

38 **Methods:** In 10 patients and 12 control subjects we explored short- and long-interval
39 intracortical inhibition (SICI, LICI; post-synaptic GABA_A and GABA_B-mediated
40 respectively) and long-interval intracortical facilitation (LICF; pre-synaptic disinhibition)
41 using transcranial magnetic stimulation.

42 **Results:** While post-synaptic GABA_B-mediated inhibition was unchanged in IGE (p=0.09),
43 LICF was reduced compared to controls (controls: 141±17% of baseline; untreated patients:
44 107±12%, p=0.2; treated patients: 79±10%, p=0.003). GABA_A-mediated inhibition was
45 reduced in untreated patients (response amplitude 56±4% of baseline vs. 26±6% in controls,
46 p=0.004) and normalised with treatment (37±12%, p=0.5 vs. controls). When measured
47 during LICI, GABA_A-mediated inhibition became excitatory in untreated IGE (response
48 amplitude 120±10% of baseline, p=0.017), but not in treated patients.

49 **Conclusions:** Pre- and post-synaptic GABA-mediated inhibitory mechanisms are altered in
50 IGE. The findings lend *in vivo* support to evidence from experimental models and *in vitro*
51 studies of human epileptic brain tissue that GABA may have a paradoxical excitatory role in
52 ictogenesis.

53 **Keywords:** transcranial magnetic stimulation, epilepsy, cortical excitability, GABA,
54 disinhibition

55

55 **Abbreviations:**

- 56 AED: anti-epileptic drug
- 57 AED_{NO}: IGE not on AEDs (subject group)
- 58 AED_{ON}: IGE on AEDs (subject group)
- 59 CS: conditioning stimulus
- 60 EEG: electroencephalography
- 61 EMG: electromyography
- 62 FDI: first dorsal interosseous (muscle)
- 63 GABAR: GABA receptor
- 64 GABA_AR: GABA_A receptor
- 65 GABA_BR: GABA_B receptor
- 66 I_{1mV}: intensity needed to evoke a MEP of 1mV amplitude
- 67 IGE: idiopathic generalised epilepsy
- 68 ISI: inter-stimulus interval
- 69 IPSP: inhibitory post-synaptic potential
- 70 JME: juvenile myoclonic epilepsy
- 71 KCC2: K⁺/Cl⁻ cotransporter 2
- 72 LCD: late cortical disinhibition
- 73 LICF: long-interval intracortical facilitation
- 74 LICl: long-interval intracortical inhibition
- 75 MEP: motor evoked potential
- 76 NKCC1: Na⁺/K⁺/2Cl⁻ cotransporter 1
- 77 PS: priming stimulus
- 78 RMT: resting motor threshold
- 79 SICI: short-interval intracortical inhibition

- 80 TLE: temporal lobe epilepsy
- 81 TMS: transcranial magnetic stimulation
- 82 TS: test stimulus
- 83 TS*: adjusted test stimulus
- 84

Accepted Manuscript

84 **Introduction**

85 Epilepsy is characterised by neuronal hyperexcitability and hypersynchronicity which
86 manifests as recurrent seizures [1-2]. The pathophysiological processes underlying epilepsy
87 in its various forms remain incompletely understood (for reviews, see Engelborghs et al. [1]
88 and McCormick and Contreras [2]) but an imbalance between excitatory and inhibitory
89 neuronal inputs is usually implicated. Critical to understanding the pathophysiology of
90 epileptogenesis and ictogenesis are abnormalities in synaptic transmission, and in particular
91 in the activity of GABAergic synaptic networks [2-5]. An improved understanding of *in vivo*
92 synaptic function in epilepsy may inform diagnosis and clinical management.

93

94 Within the central nervous system, GABAergic activity can regulate neuronal firing,
95 synchronicity and network oscillations [6]. At a cellular level, activation of post-synaptic
96 GABA receptors results in rapid transient (GABA_AR-mediated) and longer-lasting
97 (GABA_BR-mediated) inhibitory post-synaptic potentials that can modulate or gate firing of
98 the post-synaptic neuron [7-9]. Pre-synaptic GABA_BRs remain active for longer than post-
99 synaptic GABA_BRs, and regulate (reduce) further GABA release by inhibiting Ca²⁺ influx,
100 resulting in disinhibition [8, 10-11].

101

102 In human motor cortex, the activation of GABARs can be measured with TMS using paired-
103 pulse stimulation. SICI occurs when a sub-threshold conditioning pulse is delivered ~2-6ms
104 before a supra-threshold test pulse; the conditioning pulse elicits a GABA_AR-mediated IPSP
105 and thereby reduces the amplitude of the MEP to the test pulse [12-13]. The ratio of the
106 amplitude of the conditioned MEP to the MEP for the test pulse alone can be used as an index
107 of GABA_AR activation. A supra-threshold conditioning pulse results in activation of post-
108 synaptic GABA_BRs, reducing test MEP amplitudes for conditioned-test ISIs of up to ~150ms

109 (LICI) [14-16]. Pre-synaptic GABA_BRs activated by the conditioning pulse limit further
110 GABA release, and as they remain active for longer than post-synaptic GABA_BRs a period
111 arises beyond LICI when disinhibition dominates (LCD), and during which MEP amplitude
112 is increased (LICF) and SICI reduced [17-19].

113

114 As pre- and post-synaptic GABA_BRs can exert widespread influence over neuronal firing,
115 their dysfunction has been implicated in the processes of epileptogenesis and ictogenesis [2,
116 4-5, 20]. Previous TMS studies in patients with untreated IGE have reported reduced levels of
117 SICI compared to non-epileptic control subjects [21-25], suggesting a state of cortical
118 hyperexcitability with altered (decreased) cortical GABA_A activity. Normal levels of SICI
119 have been consistently reported in patients with IGE who are well controlled on AED therapy
120 [21-25], apart from those with JME in whom SICI may [23, 26] or may not [27-28] return to
121 normal levels. The effect of IGE on LICI is not certain. Although not yet explored in human
122 IGE *in vivo*, impaired GABA_BR-mediated auto-inhibition has been demonstrated in *in vitro*
123 studies of human brain tissue obtained from patients undergoing surgery for pharmaco-
124 resistant temporal lobe epilepsy [10, 29]. While GABA mediates cortical inhibition and
125 disinhibition in adults, it is known to have excitatory effects early in development [30]. An
126 excitatory role for GABA in epilepsy has also been suggested on the basis of findings in
127 animal models and surgically resected human brain tissue [31-33].

128

129 In the present study we used TMS to compare the strengths of short- and long-interval
130 intracortical inhibition and disinhibition in the motor cortex in patients with treated and
131 untreated IGE and in controls.

132

133 **Methods**

134 **Subjects**

135 Ten patients diagnosed with IGE (16-37 years of age, mean 23 years; 4 male, all right hand
136 dominant) were recruited from the Royal Perth Hospital First Seizure Clinic and from a
137 private epilepsy clinic. The diagnosis of IGE was made by an epileptologist (JWD, NDL or
138 PLS) on the basis of clinical assessment and EEG. Patients were divided into two groups
139 according to whether or not they were currently being treated with an AED (not on treatment:
140 AED_{NO}, on treatment: AED_{ON}). Further patient details are presented in Table 1. Patients
141 taking multiple AEDs were not recruited. Four patients underwent repeat studies (at least two
142 weeks apart) after commencing (patients #1, #2 and #4) or ceasing (patients #5) AED
143 treatment as part of their prescribed epilepsy management. In total, seven sets of
144 measurements (three unique, four crossover) were obtained from patients off treatment, and
145 seven from patients on AED treatment (three unique, four crossover). Apart from patient #6,
146 all patients were seizure-free for at least 3 months following testing. Twelve healthy
147 individuals (19-32 years of age, mean 23 years; nine male, all right hand dominant) without a
148 history of epilepsy in first-degree relatives were recruited as a control group. Approval for the
149 clinical arm of the study was obtained from the Royal Perth Hospital Human Ethics
150 Committee, and University of Western Australia Human Research Ethics Committee granted
151 approval for control measurements. All participants provided written informed consent
152 according to the Declaration of Helsinki.

153

154 Testing was performed at 9 AM, after a minimum of seven hours uninterrupted sleep the
155 night before. Participants abstained from alcohol in the 24 hours prior to testing and from
156 stimulant drinks (e.g. coffee, 'energy drinks') on the day of testing. The IGE group were
157 tested at least one week after their last generalised tonic-clonic seizure, and at least 24 hours

158 after any other clinical seizure type. No participants were taking medications known to alter
159 seizure threshold (other than a single AED).

160

161 **TMS**

162 MEPs were recorded from the right FDI by surface EMG (sample rate 10kHz, amplification
163 x500, filtering 0.02–20kHz). TMS was delivered through a 7cm figure-of-eight coil
164 connected to three magnetic stimulators (Magstim 200²; Magstim Co., UK) linked through a
165 custom-built device. The coil was held tangential to the head and positioned in the
166 parasagittal plane at the optimal site for activation of the right FDI (determined from initial
167 exploration over a 1cm grid). Stimuli were delivered at 0.2Hz with the FDI relaxed, and
168 peak-peak MEP amplitude was measured. RMT was determined according to the Rossini-
169 Rothwell criterion [34]. As recommended by safety guidelines, in all IGE subjects surface
170 EMG of the right deltoid muscle was monitored so as to detect intracortical spread of
171 excitation [35], and a neurologist (PLS) was present for all testing. No adverse events
172 occurred during testing.

173

174 **LICI/LICF**

175 LICI and LICF curves were generated using paired-pulse TMS. The single-pulse TMS
176 intensity needed to evoke a MEP of 1mV amplitude was first determined (I_{1mV}), and both
177 stimuli in the paired-pulse were set to this intensity. The first pulse in a pair was designated
178 the priming stimulus and the second pulse the test stimulus (Figure 1). Paired-pulses were
179 delivered at 14 ISIs spaced so as to encompass the periods of LICI and LICF (100, 150, 170,
180 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 350ms). ISIs were pseudo-randomised and
181 divided into four blocks, with eight stimuli for each ISI. At each ISI the mean TS-MEP
182 amplitude was calculated as a percentage of the mean PS-MEP. The ISIs corresponding to

183 each subject's greatest LICI and LICF were used in the triple-pulse SICI measurements
184 ($SICI_{LICI}$ and $SICI_{LICF}$). In participants with IGE who did not show LICF, the ISI with
185 greatest PS-TS amplitude was used to evaluate $SICI_{LICF}$.

186

187 **SICI**

188 Triple-pulse TMS was used to measure SICI during LICI and LICF (Figure 1). A supra-
189 threshold PS (at I_{1mV}) was followed by a paired-pulse stimulus designed to elicit SICI,
190 consisting of a sub-threshold conditioning stimulus followed 2ms later by a supra-threshold
191 test stimulus (TS*) that was intensity-adjusted so as to give a MEP of 1mV in the presence of
192 LICI or LICF. The CS was delivered at three intensities: 0.7, 0.8 and 0.9 RMT. An ISI of 2ms
193 was chosen to avoid contamination of SICI by SICF [36]. Unprimed SICI was measured in
194 the absence of a PS, with TS at I_{1mV} , and calculated from the ratio (expressed as a percentage)
195 of mean conditioned MEP amplitude (10 stimuli) to mean unconditioned test MEP amplitude
196 (10 stimuli). $SICI_{LICI}$ and $SICI_{LICF}$ were measured in the presence of a PS, and calculated
197 from mean conditioned TS* MEP amplitude to mean unconditioned TS* amplitude (10
198 stimuli). Stimuli were delivered in blocks of 40 for each of unprimed SICI, $SICI_{LICI}$ and
199 $SICI_{LICF}$, comprised of 10 conditioned stimuli at each level of RMT and 10 unconditioned
200 stimuli, interspersed pseudo-randomly.

201

202 **Data analysis**

203 Data was compared between Controls, AED_{NO} and AED_{ON}. All data are expressed as mean \pm
204 standard deviation.

205 LICI/LICF: Mixed model analysis with random individual effects was used to compare
206 responses between groups, and to compare each group's responses to baseline. Data was log

207 transformed where required to better approximate normality for inference purposes.
208 Adjustment for possible differences in baseline values did not alter results.
209 SICI: Mixed model repeated measures analysis was performed with factors GROUP and
210 RMT for each CONDITION (unprimed SICI, SICI_{LICI}, SICI_{LICF}). Responses were compared
211 between groups, and within each group responses were compared to baseline for each
212 condition. Adjustment for possible differences in baseline values did not alter results.

213

214 **Results**

215 **LICI and LICF**

216 RMT was similar between groups ($p=0.496$). There was no significant difference between
217 baseline MEP amplitudes for Controls ($1.60\pm 0.30\text{mV}$), AED_{NO} ($1.19\pm 0.15\text{mV}$) and AED_{ON}
218 ($1.35\pm 0.09\text{mV}$; $p=0.46$).

219

220 Figure 2A presents the LICI/LICF curves for each group. LICI was of similar magnitude in
221 all groups at ISI 100-150ms ($p=0.09$), with a significant overall reduction in MEP amplitude
222 compared to baseline (mean $46\pm 8\%$ of baseline, $p<0.001$). At longer ISIs (200-250ms) the
223 Control group demonstrated LICF as expected, with MEP amplitude significantly increased
224 compared to baseline (mean $141\pm 17\%$ of baseline, $p=0.015$) and peaking at 210ms ($151\pm 21\%$
225 of baseline). At these longer ISIs there was no statistically significant difference in amplitude
226 compared to baseline for AED_{NO} ($107\pm 12\%$, $p=0.56$), while for AED_{ON} the amplitude was
227 reduced, but with marginal significance ($79\pm 10\%$ of baseline, $p=0.045$). There were
228 significant differences at ISI 200-250ms when groups were compared: amplitude in AED_{ON}
229 was lower than both AED_{NO} ($p<0.001$) and Controls ($p=0.003$), while those for AED_{NO} and
230 Controls were not significantly different to each other ($p=0.2$). Stratifying AED_{ON} according
231 to specific AEDs (Figure 2B) suggests that the difference observed between AED_{ON} and

232 AED_{NO} may be due to lamotrigine. LICI and LICF values for patients tested both on and off
233 AED treatment are listed in Table 2.

234

235 **SICI**

236 There was no significant difference in TS*-MEP amplitude between groups (mean
237 1.20 ± 0.19 mV; $p=0.387$), and no difference between MEPs for PS and TS* ($p=0.245$). The
238 ISI for SICI_{LICI} was 100ms in all participants, whereas the ISI for SICI_{LICF} varied between
239 180-250ms (median 210ms, interquartile range 203-230ms). Figure 3 shows SICI as a
240 function of CS intensity (0.7-0.9RMT) for each group (Control, AED_{NO}, AED_{ON}) and each
241 stimulus combination (unprimed SICI, SICI_{LICI}, SICI_{LICF}). The mean values for unprimed
242 SICI, SICI_{LICI}, SICI_{LICF} in patients tested both on and off AED treatment are listed in Table 2.

243

244 The overall mean unprimed SICI amplitude in the Control group was $29 \pm 4\%$ of baseline.
245 Compared to this, SICI was significantly reduced during LICI ($68 \pm 11\%$ of baseline,
246 $p < 0.001$), and remained reduced during LICF ($53 \pm 7\%$ of baseline, $p < 0.001$). The difference
247 between SICI_{LICI} and SICI_{LICF} was also significant ($p=0.02$).

248

249 For the AED_{ON} group, SICI_{LICI} ($70 \pm 10\%$ of baseline) and SICI_{LICF} ($55 \pm 14\%$ of baseline) were
250 significantly reduced compared to unprimed SICI ($37 \pm 12\%$ of baseline; $p < 0.001$ and $p=0.03$,
251 respectively). Unprimed SICI and SICI_{LICI} in AED_{ON} were no different to the Control group
252 ($p=0.500$ and $p=0.360$, respectively).

253

254 For the AED_{NO} group, unprimed SICI was reduced compared to AED_{ON} and Controls at
255 CS=0.8RMT ($56 \pm 4\%$ of baseline, $p=0.001$ and $p=0.004$, respectively) and 0.9RMT ($52 \pm 8\%$
256 of baseline, $p=0.053$ and $p=0.01$, respectively). SICI_{LICI} was $120 \pm 10\%$ of baseline, indicating

257 that CS increased TS* amplitude ($p=0.017$). This was significantly different to the Control
258 ($p=0.007$) and AED_{ON} ($p=0.009$) groups, in which SICI_{LICI} was less than 100%. During LICF,
259 SICI in the AED_{NO} group was reduced compared to unprimed SICI ($72\pm 5\%$ of baseline,
260 $p=0.015$). Figure 4 shows SICI MEP waveforms from a representative participant,
261 demonstrating the expected reduction in conditioned MEP amplitude without PS, but that
262 with PS the conditioned MEP is increased in amplitude relative to the unconditioned MEP.
263
264 There was no difference in SICI_{LICF} between any groups ($p=0.980$).

265

266 Discussion

267 The present study demonstrates significant differences in cortical inhibition between
268 individuals with IGE and healthy control subjects. Although LICI was unchanged in IGE,
269 there was no evidence for the post-LICI period of facilitation (LICF) that is present in healthy
270 individuals. The strength of SICI was also reduced, and when measured during LICI, the
271 SICI protocol elicited a paradoxical excitatory rather than an inhibitory response in untreated
272 epileptics. Treatment with AEDs was associated with restoration of normal levels of SICI.
273 These findings point to altered function of GABAergic inhibition in epilepsy, and suggest
274 that under some circumstances GABA may have an excitatory rather than an inhibitory action
275 in the cortex in IGE.

276

277 The conventional GABA hypothesis of epilepsy suggests that “a reduction of GABAergic
278 inhibition results in epilepsy while an enhancement of GABAergic inhibition results in an
279 antiepileptic effect” [37]. In recent years this hypothesis has been challenged by reports of
280 GABA_ARs with excitatory effects, likely due to alterations in chloride homeostasis (for
281 reviews, see [4, 31-33, 38-40]). Activation of the GABA_AR opens Cl⁻ channels allowing a

282 flow of ions down their electrochemical gradient. The direction of this gradient is set by the
283 neuronal membrane cotransporters NKCC1 (influx of ions) and KCC2 (efflux of ions) [41].
284 *In utero*, relative over-expression of NKCC1 results in high intracellular Cl^- concentration,
285 and thus opening of the GABA_AR Cl^- channel results in a depolarising (outward) ion flow
286 [42-46]. In normal early human infant life the relative expression of NKCC1 and KCC2
287 reverses, with over-expression of KCC2, thereby lowering intracellular Cl^- concentration
288 such that GABA_AR activation induces hyperpolarisation [47-48]. *In vitro* studies of adult
289 human brain tissue resected for treatment of pharmaco-resistant TLE demonstrate
290 pathological over-expression of NKCC1 and under-expression of KCC2, in which case
291 activation of GABA_ARs may lead to Cl^- efflux and neuronal depolarisation [49-53]. These
292 same findings have also been reported in epileptogenic peritumoural adult human brain tissue
293 [54], and in combination with data from animal models suggest a potentially
294 epileptogenic/ictogenic role for GABA_ARs in epilepsy [4, 41]. Recent studies have also
295 identified mutations affecting GABAergic signalling in some individuals with familial IGE,
296 including loss-of-function mutations in Cl^- channels resulting in abnormally elevated
297 intracellular Cl^- concentration [55-57].

298

299 One possible explanation as to why $\text{SICI}_{\text{LICI}}$ facilitated MEPs is that LICI may contribute to a
300 reversal of the chloride gradient. During LICI, the GABA_BR IPSP (which is mediated by K^+
301 outflow [7, 58-59]) may reduce KCC2 activity (which depends on the K^+ gradient to
302 transport Cl^- out of the cell) and result in a temporarily higher intracellular Cl^- concentration
303 [41, 60-63]. A sufficiently high concentration could lead to Cl^- efflux when GABA_ARs are
304 activated, and therefore a depolarising response to SICI. Collapse of the Cl^- gradient with
305 subsequent depolarising responses has been demonstrated in animal models of focal and
306 generalised epilepsy [64-66] and in adult (focal) epileptic human brain tissue [10, 29].

307 Changes in K^+/Cl^- dynamics are thought to contribute to ictal and inter-ictal activity in
308 epilepsy [4, 40, 67], and may underlie the process of ictogenesis by converting a negative
309 (inhibitory) feedback loop (pyramidal cell activation of inhibitory interneurons) into a
310 positive (excitatory) loop [41, 68-69].

311

312 In keeping with our previous findings [19], in healthy individuals LICI at ISIs of 100-150ms
313 was followed by a period of intracortical facilitation (LICF) between 200-250ms, and
314 disinhibition (detectable as a reduction in SICI) was present throughout both of these periods.
315 This pattern was not observed in IGE, where LICF was absent in both treated and untreated
316 groups of patients, although disinhibition (as determined by $SICI_{LICF}$) was present albeit
317 weaker for AED_{NO}. A reduction in the strength (and possibly duration) of pre-synaptic
318 GABA_BR activity has been demonstrated in surgically resected brain tissue from adults with
319 focal epilepsy [29], and this could explain the absence of LICF with weaker $SICI_{LICF}$ in our
320 patients.

321

322 Consistent with previous studies in IGE [21-25] and one study of patients with generalised
323 epilepsy secondary to GABA_AR subunit mutation (conferring partial loss of function) [70],
324 we found a reduction in the strength of unprimed SICI in untreated epilepsy patients
325 compared to healthy controls, and interpret this as evidence of impaired GABA_AR function.

326 While this was restored by AED treatment, the number of AEDs in relation to sample size
327 does not enable this restoration of GABA_AR function to be interpreted pharmacologically.

328 However, in contrast to Badawy et al. [21-24, 71-72] we did not observe LICF in IGE.

329 Badawy et al. found no evidence of LICI in their healthy controls, whereas we found LICI in
330 both controls and IGE, suggesting that there may be an interrelationship between the presence
331 of LICI and LICF [19]. As LICI is a well-established phenomenon in healthy individuals, its

332 the absence in the Badaway et al. control groups complicates comparison with the present
333 findings.

334

335 The abnormalities in GABA-mediated measurements in the present study warrant further
336 investigation and may have clinical applications for the diagnosis and treatment of IGE. The
337 diagnosis of IGE is primarily clinical based on history and examination, with EEG performed
338 to support the diagnosis and aid in syndromal subclassification and prognostication [73].

339 However, up to ~50% of individuals who present with a seizure will have a normal inter-ictal
340 EEG (which does not exclude the diagnosis of epilepsy) and in others the EEG may be
341 abnormal yet non-diagnostic [74-75]. In these individuals, if the history is not clearly
342 diagnostic of IGE then measurement of LICF and $SICI_{LIC}$ may be a useful diagnostic
343 adjunct.

344

345 In conclusion, we investigated the relationship between pre-synaptic disinhibition and post-
346 synaptic inhibition in the motor cortex of treated and untreated IGE, and find that, during the
347 period of post-synaptic inhibition, activation of $GABA_A$ Rs may have excitatory effects. The
348 findings lend *in vivo* support to a growing body of evidence from experimental models and *in*
349 *vitro* studies of human epileptic brain tissue that GABA may have an excitatory role in
350 epilepsy. Coupled with alterations in disinhibition, the present findings point to a complex
351 modulation of pre- and post-synaptic GABAergic mechanisms in epilepsy.

352

353 **Acknowledgements:** We thank Dr Philip Tuch (Neurologist) for his assistance in patient
354 recruitment, and the patients and Control subjects who participated in the study. Financial
355 support for the study was provided by the Neuromuscular Foundation of Western Australia.

356

356 **Figure Legends:**

357 **Figure 1:** Protocol diagram. TOP: LICI/LICF curves were generated from paired-pulse TMS,
358 made up of a supra-threshold PS followed by TS (1mV MEP) delivered 100-350ms later.

359 This curve was used to identify the timing of strongest LICI () and LICF() for each
360 individual. BOTTOM: Paired- and triple-pulse TMS was used to measure LICI, LICF, and
361 SICI during both LICI and LICF. LICI/LICF was calculated at each ISI from the amplitude
362 ratio of primed-to-unprimed TS. Unprimed SICI was calculated from the amplitude ratio of
363 unconditioned-to-conditioned TS at ISI 2ms. At the two post-PS intervals corresponding to
364 LICI and LICF, TS intensity was adjusted to restore MEP amplitude to 1mV (TS*) in the
365 presence of PS and SICI was then measured by delivering a CS prior to TS*.

366

367 **Figure 2:** LICI/LICF curves: Mean paired-pulse (PS-TS) MEP amplitudes at each ISI,
368 expressed as a percentage of single-pulse baseline. Error bars represent standard error. (A)
369 All subject groups; (B) Subjects in AED_{ON} only, according to specific AEDs.

370

371 **Figure 3:** SICI curves: Mean conditioned MEP amplitudes expressed as a percentage of
372 unconditioned amplitudes. Values <100% indicate inhibition (0% corresponds to complete
373 suppression of MEPs), and values >100% indicate a facilitatory response. Error bars
374 represent standard error.

375

376 **Figure 4:** MEP waveforms (overlay of 3) from a representative IGE patient (Subject 1,
377 AED_{NO}). Without the priming stimulus (top row), conditioned MEP amplitude (CS-TS) is
378 reduced compared to unconditioned (TS) amplitude. Measurements made after a PS (during
379 LICI) show the conditioned MEP amplitude to be greater than for the unconditioned MEP.

380

381 **Tables:**382 **Table 1: Demographics of patients with idiopathic generalised epilepsy**

Patient	Gender	Age	AED	Months on current AED [#]	Epilepsy Syndrome	Inter-ictal EEG	Months since last seizure
<i>AED_{NO}</i>							
1*	F	16	-		IGETCS	GSW	3
2*	M	22	-		JME	GSW	0.3
3	F	19	-		IGETCS	GSW	9
4*	M	35	-		JAE	GSW	1
5*	M	22	-		IGETCS	GSW	27
6	F	26	-		JME	GSW, PPR	0.25
7	F	37	-		IGETCS	GSW	14
<i>AED_{ON}</i>							
1*	F	17	LTG	3	IGETCS	GSW	7
2*	M	22	VPA	0.5	JME	GSW	1
4*	M	36	VPA	8	JAE	GSW	6
5*	M	21	LTG	17	IGETCS	GSW	24
8	M	18	VPA	10	IGETCS	GSW	5
9	F	18	LTG	8	JAE	GSW	36
10	F	18	LTG	10	JAE	GSW	6

383 GSW: sporadic generalised spike and wave pattern, *IGETCS*: idiopathic generalised epilepsy
 384 with tonic-clonic seizures, *JAE*: juvenile absence epilepsy, *LTG*: lamotrigine, *PPR*:
 385 photoparoxysmal response, *VPA*: sodium valproate.

386 * indicates subject tested both on and off AEDs

387 # 'current AED' refers to both medication and dosage

388

389 **Table 2: LICI, LICF and SICI in subjects tested both on and off AED treatment**

Patient	LICI		LICF		Unprimed SICI		SICI _{LICI}		SICI _{LICF}	
	Off	On	Off	On	Off	On	Off	On	Off	On
1	53%	90%	148%	116%	35%	7%	-15%	12%	25%	13%
2	51%	63%	157%	118%	70%	88%	30%	18%	36%	65%
4	3%	12%	117%	75%	46%	41%	-28%	4%	35%	17%
5	1%	4%	65%	63%	44%	73%	-60%	#	43%	-4%

390 LICI values correspond to ISI 100ms, and LICF values correspond to each subject's peak
 391 ISIs (as described under *Methods*). All SICI values are averaged across CS 0.7-0.9RMT.

392 # unable to measure SICI_{LICI} as maximum stimulator output reached

393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442

Reference List

- [1] Engelborghs, S., D'Hooge, R. and De Deyn, P.P. Pathophysiology of epilepsy. *Acta Neurol Belg* 2000; **100**:201-213.
- [2] McCormick, D.A. and Contreras, D. On the cellular and network bases of epileptic seizures. *Annu Rev Physiol* 2001; **63**:815-846.
- [3] Casillas-Espinosa, P.M., Powell, K.L. and O'Brien, T.J. Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy. *Epilepsia* 2012; **53 Suppl 9**:41-58.
- [4] Avoli, M. and de Curtis, M. GABAergic synchronization in the limbic system and its role in the generation of epileptiform activity. *Prog Neurobiol* 2011; **95**:104-132.
- [5] Nicoll, R.A. My close encounter with GABA(B) receptors. *Biochem Pharmacol* 2004; **68**:1667-1674.
- [6] Mann, E.O. and Paulsen, O. Role of GABAergic inhibition in hippocampal network oscillations. *Trends Neurosci* 2007; **30**:343-349.
- [7] Connors, B.W., Malenka, R.C. and Silva, L.R. Two inhibitory postsynaptic potentials, and GABAA and GABAB receptor-mediated responses in neocortex of rat and cat. *J Physiol* 1988; **406**:443-468.
- [8] Davies, C.H., Davies, S.N. and Collingridge, G.L. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. *J Physiol* 1990; **424**:513-531.
- [9] McCormick, D.A. GABA as an inhibitory neurotransmitter in human cerebral cortex. *J Neurophysiol* 1989; **62**:1018-1027.
- [10] Deisz, R.A. GABA(B) receptor-mediated effects in human and rat neocortical neurones in vitro. *Neuropharmacology* 1999; **38**:1755-1766.
- [11] Luscher, C., Jan, L.Y., Stoffel, M., Malenka, R.C. and Nicoll, R.A. G protein-coupled inwardly rectifying K⁺ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. *Neuron* 1997; **19**:687-695.
- [12] Kujirai, T., Caramia, M.D., Rothwell, J.C., Day, B.L., Thompson, P.D., Ferbert, A., Wroe, S., Asselman, P. and Marsden, C.D. Corticocortical inhibition in human motor cortex. *J Physiol* 1993; **471**:501-519.
- [13] Ziemann, U., Lonnecker, S., Steinhoff, B.J. and Paulus, W. The effect of lorazepam on the motor cortical excitability in man. *Exp Brain Res* 1996; **109**:127-135.
- [14] McDonnell, M.N., Orekhov, Y. and Ziemann, U. The role of GABA(B) receptors in intracortical inhibition in the human motor cortex. *Exp Brain Res* 2006; **173**:86-93.
- [15] Valls-Sole, J., Pascual-Leone, A., Wassermann, E.M. and Hallett, M. Human motor evoked responses to paired transcranial magnetic stimuli. *Electroencephalogr Clin Neurophysiol* 1992; **85**:355-364.
- [16] Nakamura, H., Kitagawa, H., Kawaguchi, Y. and Tsuji, H. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. *J Physiol* 1997; **498 (Pt 3)**:817-823.
- [17] Chu, J., Gunraj, C. and Chen, R. Possible differences between the time courses of presynaptic and postsynaptic GABAB mediated inhibition in the human motor cortex. *Exp Brain Res* 2008; **184**:571-577.
- [18] Sanger, T.D., Garg, R.R. and Chen, R. Interactions between two different inhibitory systems in the human motor cortex. *J Physiol* 2001; **530**:307-317.
- [19] Cash, R.F., Ziemann, U., Murray, K. and Thickbroom, G.W. Late cortical disinhibition in human motor cortex: a triple-pulse transcranial magnetic stimulation study. *J Neurophysiol* 2010; **103**:511-518.

- 443 [20] Brown, J.T., Davies, C.H. and Randall, A.D. Synaptic activation of GABA(B)
444 receptors regulates neuronal network activity and entrainment. *Eur J Neurosci* 2007;
445 **25**:2982-2990.
- 446 [21] Badawy, R.A., Macdonell, R.A., Jackson, G.D. and Berkovic, S.F. Why do seizures in
447 generalized epilepsy often occur in the morning? *Neurology* 2009; **73**:218-222.
- 448 [22] Badawy, R.A., Macdonell, R.A., Berkovic, S.F., Newton, M.R. and Jackson, G.D.
449 Predicting seizure control: cortical excitability and antiepileptic medication. *Ann Neurol*
450 2010; **67**:64-73.
- 451 [23] Badawy, R.A., Vogrin, S.J., Lai, A. and Cook, M.J. Patterns of cortical
452 hyperexcitability in adolescent/adult-onset generalized epilepsies. *Epilepsia* 2013; **54**:871-
453 878.
- 454 [24] Badawy, R.A., Jackson, G.D., Berkovic, S.F. and Macdonell, R.A. Cortical
455 excitability and refractory epilepsy: a three-year longitudinal transcranial magnetic
456 stimulation study. *Int J Neural Syst* 2013; **23**:1250030.
- 457 [25] Klimpe, S., Behrang-Nia, M., Bott, M.C. and Werhahn, K.J. Recruitment of motor
458 cortex inhibition differentiates between generalized and focal epilepsy. *Epilepsy Res* 2009;
459 **84**:210-216.
- 460 [26] Pfütze, M., Reis, J., Haag, A., John, D., Hattemer, K., Oertel, W.H., Rosenow, F. and
461 Hamer, H.M. Lack of differences of motorcortical excitability in the morning as compared to
462 the evening in juvenile myoclonic epilepsy--a study using transcranial magnetic stimulation.
463 *Epilepsy Res* 2007; **74**:239-242.
- 464 [27] Manganotti, P., Bongiovanni, L.G., Fuggetta, G., Zanette, G. and Fiaschi, A. Effects
465 of sleep deprivation on cortical excitability in patients affected by juvenile myoclonic
466 epilepsy: a combined transcranial magnetic stimulation and EEG study. *J Neurol Neurosurg*
467 *Psychiatry* 2006; **77**:56-60.
- 468 [28] Manganotti, P., Bongiovanni, L.G., Zanette, G. and Fiaschi, A. Early and late
469 intracortical inhibition in juvenile myoclonic epilepsy. *Epilepsia* 2000; **41**:1129-1138.
- 470 [29] Teichgraber, L.A., Lehmann, T.N., Meencke, H.J., Weiss, T., Nitsch, R. and Deisz,
471 R.A. Impaired function of GABA(B) receptors in tissues from pharmacoresistant epilepsy
472 patients. *Epilepsia* 2009; **50**:1697-1716.
- 473 [30] Ben-Ari, Y. Excitatory actions of gaba during development: the nature of the nurture.
474 *Nat Rev Neurosci* 2002; **3**:728-739.
- 475 [31] Ben-Ari, Y. and Holmes, G.L. The multiple facets of gamma-aminobutyric acid
476 dysfunction in epilepsy. *Curr Opin Neurol* 2005; **18**:141-145.
- 477 [32] Cossart, R., Bernard, C. and Ben-Ari, Y. Multiple facets of GABAergic neurons and
478 synapses: multiple fates of GABA signalling in epilepsies. *Trends Neurosci* 2005; **28**:108-
479 115.
- 480 [33] Mathews, G.C. The dual roles of GABA in seizures and epilepsy generate more
481 excitement. *Epilepsy Curr* 2007; **7**:28-30.
- 482 [34] Rothwell, J.C., Hallett, M., Berardelli, A., Eisen, A., Rossini, P. and Paulus, W.
483 Magnetic stimulation: motor evoked potentials. The International Federation of Clinical
484 Neurophysiology. *Electroencephalogr Clin Neurophysiol Suppl* 1999; **52**:97-103.
- 485 [35] Rossi, S., Hallett, M., Rossini, P.M. and Pascual-Leone, A. Safety, ethical
486 considerations, and application guidelines for the use of transcranial magnetic stimulation in
487 clinical practice and research. *Clin Neurophysiol* 2009; **120**:2008-2039.
- 488 [36] Peurala, S.H., Muller-Dahlhaus, J.F., Arai, N. and Ziemann, U. Interference of short-
489 interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF). *Clin*
490 *Neurophysiol* 2008; **119**:2291-2297.
- 491 [37] De Deyn, P.P., Marescau, B. and MacDonald, R.L. Epilepsy and the GABA-
492 hypothesis a brief review and some examples. *Acta Neurol Belg* 1990; **90**:65-81.

- 493 [38] Deeb, T.Z., Maguire, J. and Moss, S.J. Possible alterations in GABAA receptor
494 signaling that underlie benzodiazepine-resistant seizures. *Epilepsia* 2012; **53 Suppl 9**:79-88.
- 495 [39] Kahle, K.T. and Staley, K. Altered neuronal chloride homeostasis and excitatory
496 GABAergic signaling in human temporal lobe epilepsy. *Epilepsy Curr* 2008; **8**:51-53.
- 497 [40] Loscher, W., Puskarjov, M. and Kaila, K. Cation-chloride cotransporters NKCC1 and
498 KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments.
499 *Neuropharmacology* 2013; **69**:62-74.
- 500 [41] Blaesse, P., Airaksinen, M.S., Rivera, C. and Kaila, K. Cation-chloride cotransporters
501 and neuronal function. *Neuron* 2009; **61**:820-838.
- 502 [42] Ben-Ari, Y., Cherubini, E., Corradetti, R. and Gaiarsa, J.L. Giant synaptic potentials
503 in immature rat CA3 hippocampal neurones. *J Physiol* 1989; **416**:303-325.
- 504 [43] Fukuda, A., Muramatsu, K., Okabe, A., Shimano, Y., Hida, H., Fujimoto, I. and
505 Nishino, H. Changes in intracellular Ca²⁺ induced by GABAA receptor activation and
506 reduction in Cl⁻ gradient in neonatal rat neocortex. *J Neurophysiol* 1998; **79**:439-446.
- 507 [44] Yamada, J., Okabe, A., Toyoda, H., Kilb, W., Luhmann, H.J. and Fukuda, A. Cl⁻
508 uptake promoting depolarizing GABA actions in immature rat neocortical neurones is
509 mediated by NKCC1. *J Physiol* 2004; **557**:829-841.
- 510 [45] Achilles, K., Okabe, A., Ikeda, M., Shimizu-Okabe, C., Yamada, J., Fukuda, A.,
511 Luhmann, H.J. and Kilb, W. Kinetic properties of Cl⁻ uptake mediated by Na⁺-dependent K⁺-
512 2Cl⁻ cotransport in immature rat neocortical neurons. *J Neurosci* 2007; **27**:8616-8627.
- 513 [46] Owens, D.F., Boyce, L.H., Davis, M.B. and Kriegstein, A.R. Excitatory GABA
514 responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-
515 patch recordings and calcium imaging. *J Neurosci* 1996; **16**:6414-6423.
- 516 [47] Dzhala, V.I., Talos, D.M., Sdrulla, D.A., Brumback, A.C., Mathews, G.C., Benke,
517 T.A., Delpire, E., Jensen, F.E. and Staley, K.J. NKCC1 transporter facilitates seizures in the
518 developing brain. *Nat Med* 2005; **11**:1205-1213.
- 519 [48] Kahle, K.T. and Staley, K.J. The bumetanide-sensitive Na-K-2Cl cotransporter
520 NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal
521 seizures. *Neurosurg Focus* 2008; **25**:E22.
- 522 [49] Deisz, R.A., Lehmann, T.N., Horn, P., Dehnicke, C. and Nitsch, R. Components of
523 neuronal chloride transport in rat and human neocortex. *J Physiol* 2011; **589**:1317-1347.
- 524 [50] Cohen, I., Navarro, V., Clemenceau, S., Baulac, M. and Miles, R. On the origin of
525 interictal activity in human temporal lobe epilepsy in vitro. *Science* 2002; **298**:1418-1421.
- 526 [51] Huberfeld, G., Wittner, L., Clemenceau, S., Baulac, M., Kaila, K., Miles, R. and
527 Rivera, C. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe
528 epilepsy. *J Neurosci* 2007; **27**:9866-9873.
- 529 [52] Munoz, A., Mendez, P., DeFelipe, J. and Alvarez-Leefmans, F.J. Cation-chloride
530 cotransporters and GABA-ergic innervation in the human epileptic hippocampus. *Epilepsia*
531 2007; **48**:663-673.
- 532 [53] Palma, E., Amici, M., Sobrero, F., Spinelli, G., Di Angelantonio, S., Ragozzino, D.,
533 Mascia, A., Scoppetta, C., Esposito, V., Miledi, R. and Eusebi, F. Anomalous levels of Cl⁻-
534 transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA
535 excitatory. *Proc Natl Acad Sci U S A* 2006; **103**:8465-8468.
- 536 [54] Conti, L., Palma, E., Roseti, C., Lauro, C., Cipriani, R., de Groot, M., Aronica, E. and
537 Limatola, C. Anomalous levels of Cl⁻ transporters cause a decrease of GABAergic inhibition
538 in human peritumoral epileptic cortex. *Epilepsia* 2011; **52**:1635-1644.
- 539 [55] Haug, K., Warnstedt, M., Alekov, A.K., Sander, T., Ramirez, A., Poser, B., Maljevic,
540 S., Hebeisen, S., Kubisch, C., Rebstock, J., Horvath, S., Hallmann, K., Dullinger, J.S., Rau,
541 B., Haverkamp, F., Beyenburg, S., Schulz, H., Janz, D., Giese, B., Muller-Newen, G.,
542 Propping, P., Elger, C.E., Fahlke, C., Lerche, H. and Heils, A. Mutations in CLCN2 encoding

- 543 a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. *Nat*
544 *Genet* 2003; **33**:527-532.
- 545 [56] Haug, K., Warnstedt, M., Alekov, A.K., Sander, T., Ramirez, A., Poser, B., Maljevic,
546 S., Hebeisen, S., Kubisch, C., Rebstock, J., Horvath, S., Hallmann, K., Dullinger, J.S., Rau,
547 B., Haverkamp, F., Beyenburg, S., Schulz, H., Janz, D., Giese, B., Muller-Newen, G.,
548 Propping, P., Elger, C.E., Fahlke, C. and Lerche, H. Retraction: Mutations in CLCN2
549 encoding a voltage-gated chloride channel are associated with idiopathic generalized
550 epilepsies. *Nat Genet* 2009; **41**:1043.
- 551 [57] Saint-Martin, C., Gauvain, G., Teodorescu, G., Gourfinkel-An, I., Fedirko, E., Weber,
552 Y.G., Maljevic, S., Ernst, J.P., Garcia-Olivares, J., Fahlke, C., Nabbout, R., LeGuern, E.,
553 Lerche, H., Poncer, J.C. and Depienne, C. Two novel CLCN2 mutations accelerating chloride
554 channel deactivation are associated with idiopathic generalized epilepsy. *Hum Mutat* 2009;
555 **30**:397-405.
- 556 [58] Kang, Y., Kaneko, T., Ohishi, H., Endo, K. and Araki, T. Spatiotemporally
557 differential inhibition of pyramidal cells in the cat motor cortex. *J Neurophysiol* 1994;
558 **71**:280-293.
- 559 [59] Crunelli, V. and Leresche, N. A role for GABAB receptors in excitation and
560 inhibition of thalamocortical cells. *Trends Neurosci* 1991; **14**:16-21.
- 561 [60] Staley, K.J. and Proctor, W.R. Modulation of mammalian dendritic GABA(A)
562 receptor function by the kinetics of Cl⁻ and HCO₃⁻ transport. *J Physiol* 1999; **519 (Pt 3)**:693-
563 712.
- 564 [61] Staley, K.J., Soldo, B.L. and Proctor, W.R. Ionic mechanisms of neuronal excitation
565 by inhibitory GABAA receptors. *Science* 1995; **269**:977-981.
- 566 [62] Thompson, S.M. and Gahwiler, B.H. Activity-dependent disinhibition. II. Effects of
567 extracellular potassium, furosemide, and membrane potential on ECl⁻ in hippocampal CA3
568 neurons. *J Neurophysiol* 1989; **61**:512-523.
- 569 [63] Thompson, S.M. and Gahwiler, B.H. Activity-dependent disinhibition. I. Repetitive
570 stimulation reduces IPSP driving force and conductance in the hippocampus in vitro. *J*
571 *Neurophysiol* 1989; **61**:501-511.
- 572 [64] Brown, J.T., Gill, C.H., Farmer, C.E., Lanneau, C., Randall, A.D., Pangalos, M.N.,
573 Collingridge, G.L. and Davies, C.H. Mechanisms contributing to the exacerbated
574 epileptiform activity in hippocampal slices of GABAB1 receptor subunit knockout mice.
575 *Epilepsy Res* 2003; **57**:121-136.
- 576 [65] Kantrowitz, J.T., Francis, N.N., Salah, A. and Perkins, K.L. Synaptic depolarizing
577 GABA Response in adults is excitatory and proconvulsive when GABAB receptors are
578 blocked. *J Neurophysiol* 2005; **93**:2656-2667.
- 579 [66] Thuault, S.J., Brown, J.T., Calver, A.R., Collingridge, G.L., Randall, A. and Davies,
580 C.H. Mechanisms contributing to the exacerbated epileptiform activity in hippocampal slices
581 expressing a C-terminal truncated GABA(B2) receptor subunit. *Epilepsy Res* 2005; **65**:41-51.
- 582 [67] Frohlich, F., Bazhenov, M., Iragui-Madoz, V. and Sejnowski, T.J. Potassium
583 dynamics in the epileptic cortex: new insights on an old topic. *Neuroscientist* 2008; **14**:422-
584 433.
- 585 [68] Fujiwara-Tsukamoto, Y., Isomura, Y., Imanishi, M., Fukai, T. and Takada, M.
586 Distinct types of ionic modulation of GABA actions in pyramidal cells and interneurons
587 during electrical induction of hippocampal seizure-like network activity. *Eur J Neurosci*
588 2007; **25**:2713-2725.
- 589 [69] Lillis, K.P., Kramer, M.A., Mertz, J., Staley, K.J. and White, J.A. Pyramidal cells
590 accumulate chloride at seizure onset. *Neurobiol Dis* 2012; **47**:358-366.

- 591 [70] Fedi, M., Berkovic, S.F., Macdonell, R.A., Curatolo, J.M., Marini, C. and Reutens,
592 D.C. Intracortical hyperexcitability in humans with a GABAA receptor mutation. *Cereb*
593 *Cortex* 2008; **18**:664-669.
- 594 [71] Badawy, R.A., Curatolo, J.M., Newton, M., Berkovic, S.F. and Macdonell, R.A.
595 Changes in cortical excitability differentiate generalized and focal epilepsy. *Ann Neurol*
596 2007; **61**:324-331.
- 597 [72] Badawy, R.A., Macdonell, R.A., Jackson, G.D. and Berkovic, S.F. Can changes in
598 cortical excitability distinguish progressive from juvenile myoclonic epilepsy? *Epilepsia*
599 2010; **51**:2084-2088.
- 600 [73] Koutroumanidis, M., Bourvari, G. and Tan, S.V. Idiopathic generalized epilepsies:
601 clinical and electroencephalogram diagnosis and treatment. *Expert Rev Neurother* 2005;
602 **5**:753-767.
- 603 [74] Krumholz, A., Wiebe, S., Gronseth, G., Shinnar, S., Levisohn, P., Ting, T., Hopp, J.,
604 Shafer, P., Morris, H., Seiden, L., Barkley, G. and French, J. Practice Parameter: evaluating
605 an apparent unprovoked first seizure in adults (an evidence-based review): report of the
606 Quality Standards Subcommittee of the American Academy of Neurology and the American
607 Epilepsy Society. *Neurology* 2007; **69**:1996-2007.
- 608 [75] Smith, S.J. EEG in the diagnosis, classification, and management of patients with
609 epilepsy. *J Neurol Neurosurg Psychiatry* 2005; **76 Suppl 2**:ii2-7.
- 610
- 611
- 612

612 **Tables:**613 **Table 1: Demographics of patients with idiopathic generalised epilepsy**

Patient	Gender	Age	AED	Months on current AED [#]	Epilepsy Syndrome	Inter-ictal EEG	Months since last seizure
<i>AED_{NO}</i>							
1*	F	16	-		IGETCS	GSW	3
2*	M	22	-		JME	GSW	0.3
3	F	19	-		IGETCS	GSW	9
4*	M	35	-		JAE	GSW	1
5*	M	22	-		IGETCS	GSW	27
6	F	26	-		JME	GSW, PPR	0.25
7	F	37	-		IGETCS	GSW	14
<i>AED_{ON}</i>							
1*	F	17	LTG	3	IGETCS	GSW	7
2*	M	22	VPA	0.5	JME	GSW	1
4*	M	36	VPA	8	JAE	GSW	6
5*	M	21	LTG	17	IGETCS	GSW	24
8	M	18	VPA	10	IGETCS	GSW	5
9	F	18	LTG	8	JAE	GSW	36
10	F	18	LTG	10	JAE	GSW	6

614 GSW: sporadic generalised spike and wave pattern, *IGETCS*: idiopathic generalised epilepsy
615 with tonic-clonic seizures, *JAE*: juvenile absence epilepsy, *LTG*: lamotrigine, *PPR*:
616 photoparoxysmal response, *VPA*: sodium valproate.

617 * indicates subject tested both on and off AEDs

618 # 'current AED' refers to both medication and dosage

619


620 **Table 2: LICI, LICF and SICI in subjects tested both on and off AED treatment**

Patient	LICI		LICF		Unprimed SICI		SICI _{LICI}		SICI _{LICF}	
	Off	On	Off	On	Off	On	Off	On	Off	On
1	53%	90%	148%	116%	35%	7%	-15%	12%	25%	13%
2	51%	63%	157%	118%	70%	88%	30%	18%	36%	65%
4	3%	12%	117%	75%	46%	41%	-28%	4%	35%	17%
5	1%	4%	65%	63%	44%	73%	-60%	#	43%	-4%

621 LICI values correspond to ISI 100ms, and LICF values correspond to each subject's peak
622 ISIs (as described under *Methods*). All SICI values are averaged across CS 0.7-0.9RMT.

623 # unable to measure SICI_{LICI} as maximum stimulator output reached

624



LICI / LICF

Unprimed TS (control)


TS



Primed TS

PS

TS



ISI

$$\frac{PS-TS}{TS}$$

SICI - Unprimed

Unconditioned TS (control)

TS



Conditioned TS

CS TS



$$\frac{CS-TS}{TS}$$

SICI_{LICI} / SICI_{LICF}

Primed TS* (control)

PS

TS*



Primed conditioned TS*

PS

CS TS*



$$\frac{PS-CS-TS^*}{PS-TS^*}$$

